Baiyang Pharmaceutical (301015.SZ) released its performance for the first half of the year, with a net profit attributable to the parent company of 163 million yuan, a decrease of 59.48%.

Wisdom Financial APP News, Baiyang Pharmaceuticals (301015.SZ) released its 2025 interim report, with the company's operating income totaling 3.751 billion yuan, a decrease of 6.02% year-on-year. Net profit attributable to shareholders of the listed company was 163 million yuan, a decrease of 59.48% year-on-year. Net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 177 million yuan, a decrease of 52.16% year-on-year. Basic earnings per share was 0.31 yuan.